93 related articles for article (PubMed ID: 142419)
1. Role of dopaminergic receptors in the regulation of growth hormone secretion.
Müller EE; Liuzzi A; Cocchi D; Panerai AE; Oppizzi G; Lacatelli V; Mantegazza P; Silvestrini F; Chiodini PG
Adv Biochem Psychopharmacol; 1977; 16():127-38. PubMed ID: 142419
[No Abstract] [Full Text] [Related]
2. [Huntington's chorea and somatotropic hormone: dynamic explorations in 27 cases (author's transl)].
Destée A; Petit H; Fossati P; Warot P
Rev Neurol (Paris); 1981; 137(1):21-31. PubMed ID: 6453416
[No Abstract] [Full Text] [Related]
3. Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
Hietala J; Koulu M; Scheinin M; Syvälahti E
Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):451-4. PubMed ID: 3935892
[TBL] [Abstract][Full Text] [Related]
4. [Significance of blood levels of prolactin and somatotropin as indices of pharmacological effects on the central nervous system].
Barreca T; Gallamini A; Murialdo G; Nizzo MC; Polleri A
Clin Ter; 1978 Jul; 86(2):147-59. PubMed ID: 743856
[No Abstract] [Full Text] [Related]
5. Growth hormone and prolactin response to bromocriptine in patients with Huntington's chorea.
Chalmers RJ; Johnson RH; Keogh HJ; Nanda RN
J Neurol Neurosurg Psychiatry; 1978 Feb; 41(2):135-9. PubMed ID: 24678
[TBL] [Abstract][Full Text] [Related]
6. Neuropharmacological intervention on the pituitary-hypothalamic relationship.
Tuomisto J
Ann Clin Res; 1978; 10(3):120-32. PubMed ID: 31130
[No Abstract] [Full Text] [Related]
7. [The effect of dopaminergic block on secretion of the growth hormone (author's transl)].
Hainer V; Krejcík L; Urbánek J; Malec J
Cas Lek Cesk; 1978 May; 117(19):590-2. PubMed ID: 679233
[No Abstract] [Full Text] [Related]
8. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
Ishibashi M; Yamaji T
J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and biochemical evidence for the dopamine agonistic effect of bromocriptine.
Fuxe K; Fredholm BB; Ogren SO; Agnati LF; Hökfelt T; Gustafsson JA
Acta Endocrinol Suppl (Copenh); 1978; 216():27-56. PubMed ID: 347864
[No Abstract] [Full Text] [Related]
10. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Sonsalla PK; Manzino L; Heikkila RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone secretion in neurological disorders.
Martinez-Campos A; Giovannini P; Cocchi D; Zanardi P; Parati EA; Caraceni T; Müller EE
Adv Biochem Psychopharmacol; 1981; 28():521-40. PubMed ID: 6452036
[No Abstract] [Full Text] [Related]
12. Growth hormone and changes in the secretion of thyrotropic hormone after thyrotropin-releasing hormone (TRH): ineffectiveness of dopaminergic stimulation.
Felt V; Nedvídková J
Endokrinologie; 1982 Oct; 80(2):201-6. PubMed ID: 6819130
[No Abstract] [Full Text] [Related]
13. The role of D-1 and D-2 receptors.
Schachter M; Bédard P; Debono AG; Jenner P; Marsden CD; Price P; Parkes JD; Keenan J; Smith B; Rosenthaler J; Horowski R; Dorow R
Nature; 1980 Jul; 286(5769):157-9. PubMed ID: 7402308
[TBL] [Abstract][Full Text] [Related]
14. Indirect evidence for a feedback loop mechanism between two central dopaminergic pathways: preliminary results.
Yehuda S
Commun Psychopharmacol; 1979; 3(2):115-9. PubMed ID: 467002
[No Abstract] [Full Text] [Related]
15. Central dopaminergic excitatory and inhibitory systems in Nelson's syndrome.
Nishida S; Matsuki M; Horino M; Endoh M; Kakita K; Tenku A; Oyama H
Horm Metab Res; 1982 Dec; 14(12):681-2. PubMed ID: 7152484
[No Abstract] [Full Text] [Related]
16. Growth hormone hyperresponsiveness to dopaminergic stimulation in Huntington's chorea.
Müller EE; Parati EA; Panerai AE; Cocchi D; Caraceni T
Neuroendocrinology; 1979; 28(5):313-9. PubMed ID: 155781
[TBL] [Abstract][Full Text] [Related]
17. Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Agnoli A; Ruggieri S; Baldassarre M; Rocco A; Del Roscio S; D'Urso R; Mearelli S; Falaschi P; Frajese G
Prog Clin Biol Res; 1980; 39():215-24. PubMed ID: 6773067
[No Abstract] [Full Text] [Related]
18. A neuroendocrinological investigation of patients with senile demantia of Alzheimer type. Plasma prolactin and GH responses following TRH, sulpiride, L-dopa, and bromocriptine administration.
Fujita M; Shimizu T
Bull Osaka Med Sch; 1986 Oct; 32(2):73-84. PubMed ID: 3122863
[No Abstract] [Full Text] [Related]
19. Effects of dopaminergic receptor stimulation and opioid receptor blockade on GH incretion: preliminary findings.
Ghisoli E; Benfenati F; Pancaldi L; Meringolo D; Catenacci M
Boll Soc Ital Biol Sper; 1980 Jun; 56(12):1222-5. PubMed ID: 6257257
[TBL] [Abstract][Full Text] [Related]
20. Similar response to dopaminergic or anti-dopaminergic drugs in acromegaly.
Tater D; Maudelonde T; Sudre Y; Besson G; Bercovici JP
Horm Metab Res; 1984 Feb; 16(2):104-5. PubMed ID: 6706287
[No Abstract] [Full Text] [Related]
[Next] [New Search]
